Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed/refractory acute myeloid leukemia

Yuchen Liu, Dominique R Bollino, Osman M Bah, Erin T Strovel, Tien Van Le, Jinoos Zarrabi, Sunita Philip, Rena G Lapidus, Maria R Baer, Sandrine Niyongere, Vu H. Duong, Christine C Dougherty, Jan Hendrik Beumer, Katherine D Caprinolo, Farin Kamangar, Ashkan Emadi

Blood blood.2024024837.

https://doi.org/10.1182/blood.2024024837

Published: 2024

Includes: Supplemental data

Journal Articles

Overcoming Venetoclax (Ven) Resistance through Glutamine (Gln) Depletion: Final Analysis of the Phase 1 Trial of Ven and Pegcrisantaspase (PegC) Combination in Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML)

Yuchen Liu, Dominique Bollino, Osman M Bah, Erin T Strovel, Jinoos Zarrabi, Sunita Philip, Ezzat Mostafa, Rena G Lapidus, Maria R. Baer, Sandrine Niyongere, Vu H. Duong, Christine C Dougherty, Katherine Caprinolo, Ashkan Emadi

Blood (2023) 142 (Supplement 1): 60.

https://doi.org/10.1182/blood-2023-186244

Published: 2023

Journal Articles

Comprehensive Plasma Amino Acid Analysis Following Administration of Short- and Long-Acting Erwinia Asparaginase (Crisantaspase) Demonstrated Significant Increase in Plasma Serine and Glycine Levels

Dominique R Bollino, J Preston Claiborne, Kanwal Mahmood, Xinrong Ma, Kayla M Tighe, Brandon Cooper, Rena G. Lapidus, Erin T Strovel, Ashkan Emadi

Blood (2022) 140 (Supplement 1): 8809–8810.

https://doi.org/10.1182/blood-2022-162726

Published: 2022

Journal Articles

Phase 1 Dose Escalation Trial of Pegcrisantaspase in Combination with Venetoclax in Adults with Relapsed or Refractory Acute Myeloid Leukemia

Dominique R Bollino, Yuchen Liu, Osman Mohamed Bah, Katherine Caprinolo, Jinoos Zarrabi, Sunita Philip, Ezzat Mostafa, Rena G. Lapidus, Zeba Singh, Michael Kallen, Yi Ning, Rima Koka, Maria R. Baer, Sandrine Niyongere, Vu H. Duong, Erin T Strovel, Molly Graveno, Ashkan Emadi

Blood (2022) 140 (Supplement 1): 9044–9045.

https://doi.org/10.1182/blood-2022-159621

Published: 2022

Journal Articles

Pegcrisantaspase in Combination with Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia: A Phase 1 Study

Sandrine Niyongere, Vu H. Duong, Dominique R Bollino, Rena G. Lapidus, Erin T. Strovel, Jinoos Zarrabi, Osman Mohamed Bah, Sunita Philip, Veronica Kflu, Maria R. Baer, Ashkan Emadi

Blood (2021) 138 (Supplement 1): 4433.

https://doi.org/10.1182/blood-2021-150728

Published: 2021

Journal Articles

Eight-Day Point of Care CAR T-Cell Manufacturing on Clinimacs Prodigy from Healthy Donors As a Proof-of-Concept Study

Kim G. Hankey, Tim Luetkens, Stephanie Avila, John McLenithan, John Braxton, Karen Underwood, Clarissa Saba, Rena G. Lapidus, Forat Lufti, Philip Margiotta, Jean A. Yared, Nancy M. Hardy, Ulrike Abramowski-Mock, Joerg Mittelstaet, Ron Dudek, Xiaoxuan Fan, Djordje Atanackovic, Aaron P. Rapoport, Saurabh Dahiya

Blood (2021) 138 (Supplement 1): 2851.

https://doi.org/10.1182/blood-2021-154013

Published: 2021

Journal Articles

Detailed Immunophenotypic Profiling of Peripheral Blood Immune Cells in Patients with Hematologic Malignancies after Sars-Cov-2 Infection

Forat Lutfi, MD, Jonathan Siglin, BS, Gabriela Sanchez-Petitto, MD, Ali Bukhari, MD, David Gottlieb, MD, Dong Won Kim, MD, Brandon Cooper, Michelle Fleyshman, MD, Diego De Miguel Perez, PhD, Michael Kleinberg, MD PhD, Rena G Lapidus, PhD, Aaron P. Rapoport, MD, Xiaoxuan Fan, PhD, Saurabh Dahiya, MD

Blood (2020) 136 (Supplement 1): 32.

https://doi.org/10.1182/blood-2020-143160

Published: 2020

Journal Articles

The Combination of PARP Inhibitors and DNMT Inhibitors Modulates Immune Activity and Suggests a Role for Immune Therapy in AML

Aksinija A Kogan, BS, MS, Michael Topper, BS, Susannah C Shissler, BS, Michael S Lee, BS, Dominique R Bollino, BS, Eun Yong Choi, Rena G Lapidus, PhD, Li Li, MD PhD, Donald Small, MD PhD, Maria R. Baer, MD, Tonya J Webb, PhD, Stephen Baylin, MD, Feyruz V. Rassool, BSc, PhD

Blood (2018) 132 (Supplement 1): 3886.

https://doi.org/10.1182/blood-2018-99-117294

Published: 2018

Journal Articles

KRX-101, a Novel FLT3 Inhibitor, Potently Active Against Resistant FLT3 -ITD/ FLT3 -TKD Mutant AML in Vitro and In Vivo

Herman O Sintim, PhD, M. Javad Aman, PhD, Frederick Holtsberg, PhD, Ashkan Emadi, MD PhD, Rena G Lapidus, PhD

Blood (2018) 132 (Supplement 1): 4049.

https://doi.org/10.1182/blood-2018-99-115260

Published: 2018

Journal Articles

Presence of Isocitrate Dehydrogenase (IDH) Mutations May Predict Clinical Response to Hypomethylating Agents in Patients with Acute Myeloid Leukemia (AML)

Elizabeth A. Griffiths, MD, Brandon Carter-Cooper, BS, Seda Tolu, BS, Laurie A Ford, BS, CCRC, Rena G. Lapidus, PhD, Meir Wetzler, MD, Eunice S. Wang, MD, Arash Etemadi, MD PhD, Ashkan Emadi, MD, PhD

Blood (2014) 124 (21): 3724.

https://doi.org/10.1182/blood.V124.21.3724.3724

Published: 2014

Journal Articles

Synergistic Antileukemic Effect Of Sequential Administration Of Dichloroacetate (DCA) Combined With Arsenic Trioxide (ATO) In Primary Blasts From Patients With Acute Myeloid Leukemia (AML) and FLT3-ITD AML Cell Lines

Ashkan Emadi, M.D., Ph.D., Brandon Carter-Cooper, BS, Mariola Sadowska, PhD, Omasiri Wonodi, BS, Rena G. Lapidus, PhD, Mark Levis, MD, PhD, Edward A. Sausville, MD, PhD

Blood (2013) 122 (21): 3955.

https://doi.org/10.1182/blood.V122.21.3955.3955

Published: 2013

Journal Articles

Dimeric Naphthoquinones: Novel Anti-Leukemic Agents Modulating Cellular Redox Status

Ashkan Emadi, M.D., Ph.D., Mariola Sadowska, PhD, Brandon Carter-Cooper, BS, Omasiri Wonodi, BS, Nidal Muvarak, BS, Feyruz Rassool, PhD, Anil Jaiswal, PhD, Maria R. Baer, MD, Rena G. Lapidus, PhD, Edward A. Sausville, MD, PhD

Blood (2013) 122 (21): 1290.

https://doi.org/10.1182/blood.V122.21.1290.1290

Published: 2013

Journal Articles

Single Agent Activity of the Cyclin-Dependent Kinase (CDK) Inhibitor Dinaciclib (SCH 727965) In Acute Myeloid and Lymphoid Leukemia Cells

Mariola Sadowska, PhD, Nidal Muvarak, BS, Rena G. Lapidus, PhD, Edward A. Sausville, MD, PhD, Rajat Bannerji, MD, PhD, Ivana Gojo, MD

Blood (2010) 116 (21): 3981.

https://doi.org/10.1182/blood.V116.21.3981.3981

Published: 2010

NARROW

A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed/refractory acute myeloid leukemia

Overcoming Venetoclax (Ven) Resistance through Glutamine (Gln) Depletion: Final Analysis of the Phase 1 Trial of Ven and Pegcrisantaspase (PegC) Combination in Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML)

Comprehensive Plasma Amino Acid Analysis Following Administration of Short- and Long-Acting Erwinia Asparaginase (Crisantaspase) Demonstrated Significant Increase in Plasma Serine and Glycine Levels

Phase 1 Dose Escalation Trial of Pegcrisantaspase in Combination with Venetoclax in Adults with Relapsed or Refractory Acute Myeloid Leukemia

Pegcrisantaspase in Combination with Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia: A Phase 1 Study

Eight-Day Point of Care CAR T-Cell Manufacturing on Clinimacs Prodigy from Healthy Donors As a Proof-of-Concept Study

Detailed Immunophenotypic Profiling of Peripheral Blood Immune Cells in Patients with Hematologic Malignancies after Sars-Cov-2 Infection

The Combination of PARP Inhibitors and DNMT Inhibitors Modulates Immune Activity and Suggests a Role for Immune Therapy in AML

KRX-101, a Novel FLT3 Inhibitor, Potently Active Against Resistant FLT3 -ITD/ FLT3 -TKD Mutant AML in Vitro and In Vivo

Presence of Isocitrate Dehydrogenase (IDH) Mutations May Predict Clinical Response to Hypomethylating Agents in Patients with Acute Myeloid Leukemia (AML)

Synergistic Antileukemic Effect Of Sequential Administration Of Dichloroacetate (DCA) Combined With Arsenic Trioxide (ATO) In Primary Blasts From Patients With Acute Myeloid Leukemia (AML) and FLT3-ITD AML Cell Lines

Dimeric Naphthoquinones: Novel Anti-Leukemic Agents Modulating Cellular Redox Status

Single Agent Activity of the Cyclin-Dependent Kinase (CDK) Inhibitor Dinaciclib (SCH 727965) In Acute Myeloid and Lymphoid Leukemia Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only